Volatility returned to the market in the first quarter of 2018, thanks largely to inflation and trade policy concerns. Healthcare stocks were not immune to the wild swings, as a double-digit gain in sector early in the quarter was erased by the end of March. Generally speaking, an aging global population provides a tailwind of demand for the sector, but also heightens scrutiny of industry practices. Companies in the sector continue to evaluate partnerships and mergers, as they position themselves for a changing healthcare landscape. This is even happening outside of Healthcare, as Amazon, JP Morgan and Berkshire Hathaway are teaming up to try to lower costs for their employees. Details of their plan are scarce, so at this point the market is forced to speculate about possible effects on the sector.
The Saratoga Health & Biotechnology Portfolio has exposure to a number of areas we find attractive, including pharmaceuticals and drug distribution, as well as insurers and biotechnology.
Information contained herein was obtained from recognized statistical services and other sources believed to be reliable and we therefore cannot make any representation as to its completeness or accuracy. Any statements not of a factual nature constitute opinions which are subject to change without notice.
Investors should carefully consider the investment objectives, risks, charges and expenses of the Saratoga Advantage Trust mutual funds. This and other important information about the Saratoga Advantage Trust's funds is contained in the prospectus, which can be obtained by clicking here, or by calling (800) 807-FUND, and which should be read carefully before investing. The Saratoga Advantage Trust's funds are distributed by Northern Lights Distributors, LLC, member FINRA/SIPC. Saratoga Capital Management, LLC is not affiliated with Northern Lights Distributors, LLC. 4/18 © Saratoga Capital Management, LLC; All Rights Reserved.